Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Investigated for use/treatment in kidney cancer, melanoma, renal cell carcinoma, lymphoma (unspecified), colorectal cancer, and brain cancer.
- Mechanism
- Curator reviewed
HSPPC-96 is a protein peptide complex consisting of a 96 kDa heat shock protein (Hsp), gp96, and an array of gp96-associated cellular peptides. Immunisation with HSPPC-96 induces T-cell specific immunity against these peptides; gp96 is not immunogenic per se. The non-covalent binding of gp96 to peptides is neither selective nor restricted to cell types. Thus, the collection of gp96-associated peptides represents the antigenic peptide pool of a cell; this is the basis of the peptide-specific immunogenicity elicited by HSPPC-96.
- Primary indication
- Investigated for use/treatment in kidney cancer, melanoma, renal cell carcinoma, lymphoma (unspecified), colorectal cancer, and brain cancer.Curator reviewed
- Code names
- HSPPC-96
Resolves to
What you can answer from here — as of September 19, 2023
Which companies are running trials of Vitespen, in which indications and phases, and which of those programs are still active?